Worldwide Liquid Biopsy Market Outlook 2020-2024 Including COVID-19 Impact Analysis
DUBLIN, June 18, 2020 /PRNewswire/ -- The "Liquid Biopsy Markets by Cancer Type and by Usage Type with Impact of COVID-19 Pandemic. Incuding Executive and Consultant Guides and Customized Forecasting and Analysis 2020-2024" report has been added to ResearchAndMarkets.com's offering.
The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Potential are all explored in this report. What is the impact of the COVID pandemic on the Liquid Biopsy market? This report provides detailed analysis.
Circulating Tumor Cells? Cell-Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find opportunities and pitfalls. Understand growth expectations and the ultimate potential market size.
A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread screening for all types of cancers with a blood test.
GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The company is now working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has just moved out of the development phase and into the growth phase. The impact on the health care industry is enormous. The report forecasts the market size out to 2024. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.
The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring.
Key Topics Covered:
1. Introduction and Market Definition
2. Market Overview
2.1 Players in a Dynamic Market
2.2 Using Biopsies
2.3 Biopsy Sites
2.4 The Situation Today - Biopsy Analysis
2.5 Evidence of Cancer - Liquid Biopsy Technology
2.6 Cancer Treatment Protocol Under Siege
2.7 Structure of Industry Plays a Part
3. Market Trends
3.1 Factors Driving Growth
3.2 Factors Limiting Growth
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role
3.4 Diagnostic Technology Development
3.4.1 Next Generation Sequencing Fuels a Revolution
3.4.2 Impact of NGS on pricing
3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
3.4.4 CGES Testing, A Brave New World
3.4.5 Biochips/Giant magnetoresistance based assay
4. Liquid Biopsy Recent Developments
5. Profiles of Key Players
- Abbott Diagnostics
- AccuraGen Inc
- Acuamark Diagnostics
- Admera Health, LLC
- Agena Bioscience, Inc
- Agilent
- Amoy Diagnostics Co., Ltd.
- Anchor Dx
- ANGLE plc
- ApoCell, Inc.
- ArcherDx, Inc
- Asuragen
- AVIVA Biosciences
- Baylor Miraca Genetics Laboratories
- Beckman Coulter, Inc.
- Becton, Dickinson and Company
- BGI Genomics Co. Ltd
- Bioarray Genetics
- Biocartis
- Biocept, Inc
- Biodesix Inc
- BioFluidica
- bioMrieux Diagnostics
- Bioneer Corporation
- Bio-Rad Laboratories, Inc
- Bio-Techne
- Bioview
- Bolidics
- Boreal Genomics
- Caris Molecular Diagnostics
- CellMax Life
- Cepheid (now Danaher)
- Chronix Biomedical
- Circulogene
- Clinical Genomics
- Cynvenio
- Cytolumina Technologies Corp
- CytoTrack
- Datar Cancer Genetics Limited
- Diagenode Diagnostics
- Diagnologix LLC
- Enzo Life Sciences, Inc
- Epic Sciences
- Epigenomics AG
- Eurofins Scientific
- Exosome Diagnostics
- Exosome Sciences
- Fluidigm Corp
- Fluxion Biosciences
- Foundation Medicine
- Freenome
- GeneFirst Ltd.
- Genetron Health (Beijing) Co., Ltd
- Genomic Health
- GILUPI Nanomedizin
- Grail, Inc.
- Guardant Health
- HansaBiomed
- HeiScreen
- Helomics
- Horizon Discovery
- iCellate
- Illumina
- Incell Dx
- Inivata
- Integrated Diagnostics
- Janssen Diagnostics
- MDNA Life SCIENCES, Inc
- MDx Health
- Menarini Silicon Biosystems
- Millipore Sigma
- Miltenyi Biotec
- miR Scientific
- Molecular MD
- Myriad Genetics/Myriad RBM
- NantHealth, Inc.
- Natera
- NeoGenomics
- New Oncology
- Novogene Bioinformatics Technology Co., Ltd.
- Oncocyte
- OncoDNA
- Oxford Nanopore Technologies
- Perkin Elmer
- Personal Genome Diagnostics
- PrecisionMed
- Promega
- Qiagen Gmbh
- Quidel
- Rarecells SAS
- RareCyte
- Resolution Biosciences, Inc
- Roche Molecular Diagnostics
- Screencell
- Siemens Healthineers
- simfo GmbH
- Singlera Genomics Inc
- SRI International
- Sysmex Inostics
- Tempus Labs, Inc
- Thermo Fisher Scientific Inc.
- Thrive Earlier Detection
- Trovagene
- Volition
6. The Global Market for Liquid Biopsy Diagnostics
7. Global Liquid Biopsy Diagnostic Markets - By Cancer
8. Global Liquid Biopsy Diagnostic Markets - by Usage
For more information about this report visit https://www.researchandmarkets.com/r/f4m5xg
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article